Neuland Laboratories logo

Neuland Laboratories

NEULANDLAB NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹30,189 Cr
Volatility
Moderate
P/E Ratio
60.66
EBITDA
₹605 Cr
Return on Equity
19.42%
Debt to Equity
0.16
Book Value
₹1,460.31
EPS
₹249.83
52W High
₹24,225
52W Low
₹11,500

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.5% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 16.1 times its book value
  • Promoter holding has decreased over last 3 years: -3.41%

Growth Rate

Revenue Growth
37.13% higher than 3Y
Net Income Growth
39.95% higher than 3Y
Cash Flow Change
9.22% lower than 3Y
ROE
13.83% lower than 3Y
ROCE
11.7% higher than 3Y
EBITDA Margin (Avg.)
28.27% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2h ago
AI opinion · based on fundamentals
Risk high

Neuland Laboratories, a specialty API manufacturer, has delivered exceptional recent growth with TTM sales up 78% and TTM profit up 278%, resulting in a market cap of ₹30,189 Cr. However, the stock trades at a PE of 61.3x and 16.3x book value, reflecting aggressive pricing relative to its longer-term compounded sales CAGR of 15% over 10 years.

Bull Case 8
  • TTM revenue growth of 78% signals a significant acceleration in business momentum, far exceeding the 10-year compounded sales CAGR of 15%
  • TTM profit growth of 278% indicates massive operating leverage kicking in, suggesting the company's cost structure is scaling efficiently with higher revenues
  • 5-year compounded profit CAGR of 39% demonstrates sustained earnings power, not just a one-off spike
  • ROE has improved to 21% in the last year from a 10-year average of 14%, showing improving capital efficiency and returns to shareholders
  • 3-year ROE of 20% and 5-year ROE of 18% show a consistently rising return profile over multiple periods
  • 10-year stock CAGR of 37% reflects long-term wealth creation, with the company compounding sales at 15% and profits at 29% over the same period
  • Company is expected to deliver another strong quarter, suggesting near-term earnings momentum remains intact
  • 5-year compounded sales CAGR of 17% provides a solid baseline growth trajectory even before the recent acceleration
Bear Case 7
  • PE ratio of 61.3x is significantly elevated for a pharmaceutical API company, leaving limited margin of safety if growth decelerates
  • Price-to-book ratio of 16.3x is extremely stretched, implying the market is pricing in years of high-growth execution with little room for disappointment
  • Promoter holding has declined by 3.41% over the last 3 years, which may signal reduced insider confidence or dilution at elevated valuations
  • Dividend yield of just 0.14% indicates minimal cash return to shareholders despite strong profitability, suggesting the stock is almost entirely a capital appreciation play
  • The gap between TTM sales growth of 78% and the 10-year CAGR of 15% raises sustainability questions — mean reversion to mid-teens growth would make current valuations hard to justify
  • 1-year stock CAGR of 47% after a 3-year CAGR of 88% suggests significant returns have already been front-loaded, increasing the risk of multiple compression
  • TTM profit growth of 278% against a 3-year profit CAGR of 30% suggests a low base effect may be inflating recent growth figures, which may not be repeatable

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Headwinds 1
  • Major fund dumps 2.12% stake Aug 17

    Malabar India Fund sold 2,72,634 shares in the open market, cutting its holding from 7.18% to 5.06%. Significant institutional selling can signal reduced conviction and add near-term supply pressure.

Positives 1
  • ₹126Cr land buy for expansion Sep 7

    Board approved ₹126 crore capex to acquire 134 acres in Kakinada for future capacity expansion, funded entirely through internal accruals. Signals confidence in long-term growth without leveraging the balance sheet.

Neutral 1
  • Analyst meets scheduled in Hyderabad Sep 9

    Neuland Labs scheduled group meetings with institutional investors in Hyderabad on September 15 and 17, 2026, as part of its regular investor relations calendar.

TL;DR: Neuland Labs is investing aggressively in future capacity with a ₹126 crore self-funded land acquisition in Kakinada, reflecting strong balance sheet confidence and a long-term growth runway in the CMS/API space. However, Malabar India Fund's 2.12% stake sale introduces near-term overhang risk. The fundamental trajectory remains expansion-oriented, and upcoming analyst meets in mid-September could provide further clarity on management's capex roadmap and order pipeline.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
363
418
393
385
440
311
398
328
293
514
440
776
642
Expenses
266
280
272
278
316
249
311
277
258
359
363
469
419
Operating Profit
97
137
121
107
123
62
87
51
34
156
77
307
223
OPM %
27%
33%
31%
28%
28%
20%
22%
16%
12%
30%
18%
40%
35%
Other Income
2
3
2
5
25
4
60
7
8
2
8
12
8
Interest
2
4
4
4
3
1
2
2
5
5
7
7
7
Depreciation
14
15
15
16
16
16
16
17
20
23
24
25
27
PBT
83
122
104
92
130
49
128
39
18
129
54
287
198
Tax %
26%
27%
22%
27%
25%
34%
20%
29%
21%
25%
26%
26%
25%
Net Profit
62
89
81
68
98
33
102
28
14
97
41
213
148
EPS in Rs
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.68
10.83
75.49
31.62
166
115
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
469
510
579
527
667
763
937
951
1,191
1,559
1,477
2,023
2,372
Expenses
402
430
472
477
608
661
790
807
918
1,096
1,146
1,443
1,609
Operating Profit
67
80
106
51
58
102
147
144
273
463
331
580
763
OPM %
14%
16%
18%
10%
9%
13%
16%
15%
23%
30%
22%
29%
32%
Other Income
0
2
1
4
3
4
16
0
9
12
90
25
31
Interest
27
24
21
19
16
22
18
14
13
14
8
24
26
Depreciation
15
16
19
22
26
31
40
49
53
60
66
92
98
PBT
25
42
67
14
20
53
105
82
216
401
346
489
669
Tax %
36%
36%
30%
13%
19%
69%
23%
22%
24%
25%
25%
26%
—
Net Profit
16
27
47
12
16
16
81
64
164
300
260
364
498
EPS in Rs
17.96
30.75
52.74
13.57
12.81
12.63
62.85
49.74
127
234
203
284
388
Div. Payout %
8%
7%
0%
0%
0%
16%
8%
10%
8%
6%
6%
12%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
9
9
13
13
13
13
13
13
13
13
Reserves
152
178
537
549
686
697
774
828
981
1,270
1,512
1,862
Borrowings
188
182
192
319
231
264
182
241
128
95
157
301
Other Liabilities
162
155
148
194
200
257
356
302
457
454
498
754
Total Liabilities
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Fixed Assets
123
139
466
475
542
653
716
767
758
824
955
1,177
CWIP
41
40
20
126
104
24
17
20
41
46
48
211
Investments
7
7
8
8
8
8
7
4
1
1
109
2
Other Assets
340
337
393
463
476
547
585
592
781
962
1,068
1,541
Total Assets
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
13
45
39
11
70
57
189
60
237
261
317
347
Investing
-14
-20
-42
-116
-77
-49
-84
-95
-61
-150
-298
-423
Financing
1
-24
0
105
12
-5
-114
38
-136
-69
25
21
Net Cash Flow
0
1
-4
0
5
3
-9
3
40
42
44
-55
Free Cash Flow
-1
26
-2
-121
7
9
84
-37
173
119
112
-50
CFO/OP
33
70
52
28
128
61
132
56
103
81
119
78
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
100
85
114
134
90
91
85
90
111
87
78
98
Inventory Days
170
182
186
266
191
209
205
227
211
220
238
245
Days Payable
167
121
118
189
118
110
126
100
129
121
156
129
Cash Conversion Cycle
103
147
182
211
162
190
164
216
193
187
160
214
Working Capital Days
11
26
44
38
138
137
60
74
81
88
76
75
ROCE %
16%
18%
16%
4%
4%
8%
11%
10%
21%
33%
19%
26%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Neuland Laboratories insights

71 extracted metrics + investor summaries across FY09–FY27.

Log in — free

Shareholding Pattern

Promot.32.62%Public22.88%Others6.91%DIIs16.51%FIIs21.08%As ofJun 2026
2.29% of promoter holding pledged as of Jun 2026

Documents

Frequently Asked Questions about Neuland Laboratories

What does Neuland Laboratories Ltd do?
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]
Where is Neuland Laboratories Ltd (NEULANDLAB) listed?
Neuland Laboratories Ltd trades as NEULANDLAB on the NSE and under code 524558 on the BSE.
Which sector does Neuland Laboratories Ltd belong to?
Neuland Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Neuland Laboratories Ltd?
Neuland Laboratories Ltd has a market capitalisation of ₹30,189 Cr, which places it in the Large Cap band.
What is the PE ratio of Neuland Laboratories Ltd?
Neuland Laboratories Ltd trades at a PE ratio of 60.66, on earnings per share of ₹249.83, against a book value of ₹1,460.31 per share.
What is the 52-week high and low of Neuland Laboratories Ltd?
Over the last 52 weeks Neuland Laboratories Ltd has traded between ₹11,500 and ₹24,225.
Does Neuland Laboratories Ltd pay dividends?
Neuland Laboratories Ltd has a dividend yield of 0.14%.
What is the Return on Equity (ROE) of Neuland Laboratories Ltd?
Neuland Laboratories Ltd reported a return on equity of 19.42%. Its debt-to-equity ratio is 0.16.

Company Information

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Website neulandlabs.com
CEO Dr. Davuluri Rama Mohan Rao
Employees 1,794
Listed 2008-10-13
Face Value ₹ 10
Issued Size 1,28,29,889

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEULANDLAB.md for Neuland Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List